Bone Metabolism Unit, Creighton University School of Medicine, 601 North 30th Street, Suite 6718, Omaha, Nebraska 68131, USA.
J Clin Endocrinol Metab. 2013 Mar;98(3):1137-46. doi: 10.1210/jc.2012-3106. Epub 2013 Feb 5.
Serum 25-hydroxyvitamin D (25OHD) is lower in women with darker skin color. Is it due to lower skin production, lower absorption, or different metabolism of vitamin D?
The objective of the study was to measure the effect of vitamin D3 on serum 25OHD and serum PTH in older African American women with vitamin D insufficiency and the serum 25OHD 20 ng/mL or less (<50 nmol/L). The results can be used to estimate the Recommended Dietary Allowance (RDA).
This was a randomized, double-blind placebo trial at Creighton University Medical Center and Indiana University Medical Center.
Participants were 110 healthy older African American women.
The intervention consisted of participants randomly assigned to placebo, vitamin D3 400, 800, 1600, 2400, 3200, 4000, or 4800 IU daily; calcium supplements were given to maintain total calcium intake of 1200-1400 mg/d.
Change in serum 25OHD and serum PTH levels at 12 months was measured.
Mean baseline serum 25OHD was 13 ng/mL (33 nmol/L). On 4800 IU, serum 25OHD averaged 50 ng/mL (125 nmol/L) compared with 47 ng/mL (117 nmol/L) in Caucasian women. Serum PTH at 12 months decreased significantly (P = .008) when related to serum 25OHD but not dose. Hypercalcemia occurred in 7% and hypercalciuria in 15%. Events were unrelated to vitamin D dose.
Vitamin D3 800 IU increased serum 25OHD greater than 20 ng/mL (>50 nmol/L) in 97.5% of the African American women just as it did in the Caucasian women, and therefore, the RDA is the same for both groups. Because absorption and metabolism of oral vitamin D absorption is similar in both groups, lower levels of serum 25OHD in African Americans must be due to lower production of vitamin D in skin.
血清 25-羟维生素 D(25OHD)在肤色较深的女性中较低。这是由于皮肤产生较少、吸收较少,还是维生素 D 的代谢不同?
本研究的目的是测量维生素 D3 对维生素 D 不足的老年非裔美国女性血清 25OHD 和血清 PTH 的影响,以及血清 25OHD<20ng/ml(<50nmol/L)。结果可用于估计推荐膳食允许量(RDA)。
这是在克赖顿大学医学中心和印第安纳大学医学中心进行的一项随机、双盲安慰剂试验。
参与者为 110 名健康的老年非裔美国女性。
干预措施包括参与者随机分配至安慰剂、维生素 D3400、800、1600、2400、3200、4000 或 4800IU 每日;给予钙补充剂以维持总钙摄入量 1200-1400mg/d。
12 个月时血清 25OHD 和血清 PTH 水平的变化。
平均基线血清 25OHD 为 13ng/ml(33nmol/L)。服用 4800IU 时,血清 25OHD 平均为 50ng/ml(125nmol/L),而白人女性为 47ng/ml(117nmol/L)。12 个月时,血清 PTH 显著下降(P=0.008),与血清 25OHD 相关,但与剂量无关。高钙血症发生率为 7%,高钙尿症发生率为 15%。这些事件与维生素 D 剂量无关。
维生素 D3800IU 使 97.5%的非裔美国女性血清 25OHD 升高至>20ng/ml(>50nmol/L),与白人女性相同,因此,两组的 RDA 相同。由于两组口服维生素 D 吸收的吸收和代谢相似,非裔美国人血清 25OHD 水平较低一定是由于皮肤产生的维生素 D 较少。